Edition:
United States

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

85.10USD
16 Feb 2018
Change (% chg)

$-0.35 (-0.41%)
Prev Close
$85.45
Open
$85.40
Day's High
$85.48
Day's Low
$85.10
Volume
993,118
Avg. Vol
893,008
52-wk High
$86.28
52-wk Low
$19.62

Latest Key Developments (Source: Significant Developments)

Celgene Announces Offering Of Senior Unsecured Notes
Thursday, 8 Feb 2018 08:55am EST 

Feb 8 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES OFFERING OF SENIOR UNSECURED NOTES.CELGENE CORP - EXPECTS TO USE NET PROCEEDS FROM OFFERING TO FINANCE A PORTION OF ACQUISITION OF JUNO THERAPEUTICS.  Full Article

Celgene Is In Talks To Buy Juno Therapeutics -WSJ Reporter Tweet‍​
Tuesday, 16 Jan 2018 04:49pm EST 

Jan 16 (Reuters) - :CELGENE IS IN TALKS TO BUY JUNO THERAPEUTICS -WSJ REPORTER TWEET‍​.  Full Article

Juno Therapeutics And Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
Wednesday, 20 Dec 2017 08:00am EST 

Dec 20 (Reuters) - Juno Therapeutics Inc ::JUNO THERAPEUTICS AND THERMO FISHER SCIENTIFIC ANNOUNCE CAR T MANUFACTURING PARTNERSHIP.JUNO THERAPEUTICS - OBTAINED RIGHTS TO USE CTS DYNABEADS CD3/CD28 MAGNETIC BEADS FOR CLINICAL, COMMERCIAL MANUFACTURING PROCESSES FOR CAR T THERAPIES.JUNO THERAPEUTICS INC - NO OTHER TERMS FROM THIS TRANSACTION WERE DISCLOSED.  Full Article

Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center
Wednesday, 6 Dec 2017 09:00am EST 

Dec 6 (Reuters) - Juno Therapeutics Inc ::JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION.JUNO THERAPEUTICS - THREE LICENSE DEALS TO ADVANCE PROGRAM IN MULTIPLE MYELOMA USING GAMMA SECRETASE INHIBITORS WITH BCMA-DIRECTED CAR T CELLS.JUNO THERAPEUTICS INC - THROUGH ITS AGREEMENT WITH ELI LILLY AND COMPANY, JUNO WILL ACQUIRE A LICENSE TO GSI KNOWN AS LY3039478.JUNO THERAPEUTICS- CO TO ALSO GAIN RIGHTS TO INTELLECTUAL PROPERTY WITHIN FIELD OF COMBINATIONS OF GSIS, BCMA-DIRECTED ENGINEERED T CELLS IN OTHER DEALS.JUNO THERAPEUTICS INC - NO OTHER TERMS FROM THESE THREE TRANSACTIONS WERE DISCLOSED.  Full Article

Juno Therapeutics reports Q3 adjusted loss per share ‍$0.73​
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Juno Therapeutics Inc :Juno Therapeutics reports third quarter 2017 financial results.Juno Therapeutics Inc - qtrly ‍revenue $44.8 million versus $20.8 million​.Juno Therapeutics Inc - qtrly loss per share ‍$1.12​.Juno Therapeutics Inc - qtrly adjusted loss per share ‍$0.73​.Juno Therapeutics Inc - ‍expects to be in lower half of 2017 cash burn guidance​.Q3 earnings per share view $-0.80, revenue view $16.2 million -- Thomson Reuters I/B/E/S.  Full Article

Juno Therapeutics and Trianni sign licensing agreement for use of Trianni Transgenic Mouse platform
Wednesday, 18 Oct 2017 08:00am EDT 

Oct 18 (Reuters) - Juno Therapeutics Inc : :Trianni and Juno Therapeutics sign licensing agreement for use of Trianni Transgenic Mouse platform.Juno - to use Trianni Mouse with its single cell sequencing technology to identify fully-human binders for conversion to chimeric antigen receptors.Juno Therapeutics Inc - ‍no financial details were disclosed​.  Full Article

Juno Therapeutics files for offering of common stock aggregate offering price of $225 mln - SEC Filing‍​
Wednesday, 20 Sep 2017 04:17pm EDT 

Sept 20 (Reuters) - Juno Therapeutics Inc :Juno Therapeutics Inc - Files for offering of common stock; aggregate offering price of $225 million - SEC Filing‍​.  Full Article

Juno Therapeutics qtrly ‍loss per share $0.96
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - Juno Therapeutics Inc JUNO.O:Juno Therapeutics reports second quarter 2017 financial results.Juno Therapeutics Inc- ‍revenue for three months ended June 30, 2017 was $21.3 million compared to $27.6 million​.Qtrly ‍loss per share $0.96; qtrly adjusted loss per share $0.74​.Juno Therapeutics Inc- Juno reaffirms 2017 cash burn​.Juno Therapeutics Inc- ‍2017 operating burn estimated to be between $245 million and $275 million​.Q2 earnings per share view $-0.72, revenue view $15.8 million -- Thomson Reuters I/B/E/S.  Full Article

Juno Therapeutics says court decides it lacks jurisdiction over Kite Pharma lawsuit
Wednesday, 14 Jun 2017 09:00am EDT 

June 14 (Reuters) - Juno Therapeutics Inc ::Court decides it lacks jurisdiction before FDA approval occurs.Juno Therapeutics - U.S. District Court for district of Delaware decided it lacked jurisdiction at this time over a lawsuit filed against Kite Pharma.Juno Therapeutics - court cited absence of evidence that FDA approval of Kite's axicabtagene ciloleucel "is expected on defendant's BLA in immediate future.  Full Article

Juno Therapeutics reports Q1 loss per share $0.79
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Juno Therapeutics Inc :Juno Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.79.Juno Therapeutics Inc - Revenue for three months ended March 31, 2017 and 2016 was $19.3 million and $9.8 million.Q1 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.Juno Therapeutics Inc - Reaffirms 2017 cash burn of between $270 million and $300 million.Juno Therapeutics Inc - Capital expenditures, net of tenant improvement allowances, estimated to be between $22 million and $27 million for FY.  Full Article

France's Cellectis wins U.S patents for gene editing technology

PARIS The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.